$CBIH
Cannabis Bioscience International Holdings, Inc. Stock $cbih

$cbih Overview Financials Valuation SEC Filings Company Website

2024 Q3 Form 10-K Financial Statement

#000168316824006402 Filed on September 16, 2024

Income Statement

Concept	2024 Q3	2024 Q2	2024
Revenue	$178.9K		$248.8K
YoY Change	145.65%		-21.46%
Cost Of Revenue	$8.362K		$45.60K
YoY Change	-5.19%		-51.2%
Gross Profit	$170.5K		$203.2K
YoY Change	166.44%		-9.01%
Gross Profit Margin	95.33%		81.68%
Selling, General & Admin
YoY Change
% of Gross Profit
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses	$268.1K		$689.4K
YoY Change	11.36%		-42.87%
Operating Profit	-$97.60K		-$486.1K
YoY Change	-44.79%		-50.56%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net	$21.30K		-$165.2K
YoY Change	-525.55%		235.73%
Pretax Income
YoY Change
Income Tax			$0.00
% Of Pretax Income
Net Earnings	-$76.31K		-$651.3K
YoY Change	-58.03%		-36.92%
Net Earnings / Revenue	-42.66%		-261.75%
Basic Earnings Per Share	$0.00		$0.00
Diluted Earnings Per Share	$0.00		$0.00
COMMON SHARES
Basic Shares Outstanding	10.43B shares	10.38B shares	10.32B shares
Diluted Shares Outstanding	10.46B shares		10.32B shares

Balance Sheet

Concept	2024 Q3	2024 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments
YoY Change
Cash & Equivalents	$969.00	$755.00
Short-Term Investments
Other Short-Term Assets	$598.00	$598.00
YoY Change
Inventory
Prepaid Expenses
Receivables	$17.18K	$20.14K
Other Receivables
Total Short-Term Assets	$18.74K	$21.49K
YoY Change		10.43%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets	$27.54K	$35.67K
YoY Change		49.12%
TOTAL ASSETS
Total Short-Term Assets	$18.74K	$21.49K
Total Long-Term Assets	$27.54K	$35.67K
Total Assets	$46.28K	$57.16K
YoY Change		31.76%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable
YoY Change
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt
YoY Change
Long-Term Debt Due	$7.054K	$7.054K
YoY Change		-51.66%
Total Short-Term Liabilities	$852.1K	$881.9K
YoY Change		128.74%
LONG-TERM LIABILITIES
Long-Term Debt	$249.5K	$249.4K
YoY Change		-0.06%
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities	$249.5K	$254.3K
YoY Change		1.91%
TOTAL LIABILITIES
Total Short-Term Liabilities	$852.1K	$881.9K
Total Long-Term Liabilities	$249.5K	$254.3K
Total Liabilities	$1.102M	$1.136M
YoY Change		78.91%
SHAREHOLDERS EQUITY
Retained Earnings	-$5.410M	-$5.334M
YoY Change		13.91%
Common Stock	$0.00	$0.00
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$1.055M	-$1.079M
YoY Change
Total Liabilities & Shareholders Equity	$46.28K	$57.16K
YoY Change		31.76%

Cashflow Statement

Concept	2024 Q3	2024
OPERATING ACTIVITIES
Net Income	-$76.31K	-$651.3K
YoY Change	-58.03%	-36.92%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities	-$30.41K	-$479.4K
YoY Change	-59.24%	-46.64%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$30.63K	$471.2K
YoY Change	-56.53%	-46.16%
NET CHANGE
Cash From Operating Activities	-$30.41K	-$479.4K
Cash From Investing Activities
Cash From Financing Activities	$30.63K	$471.2K
Net Change In Cash	$214.00	-$8.158K
YoY Change	-105.14%	-64.64%
FREE CASH FLOW
Cash From Operating Activities	-$30.41K	-$479.4K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2024	dei	Entity Central Index Key EntityCentralIndexKey	0001411057
CY2023	CBIH	Change In Value Of Common Stock ChangeInValueOfCommonStock		usd
CY2023	CBIH	Exchange Of Series B Preferred Stock For Common Stock ExchangeOfSeriesBPreferredStockForCommonStock		usd
CY2024	dei	Document Type DocumentType	10-K
CY2024	dei	Document Annual Report DocumentAnnualReport	true
CY2024	dei	Document Period End Date DocumentPeriodEndDate	2024-05-31
CY2024	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--05-31
CY2024	dei	Document Transition Report DocumentTransitionReport	false
CY2024	dei	Entity File Number EntityFileNumber	333-267039
CY2024	dei	Entity Registrant Name EntityRegistrantName	CANNABIS BIOSCIENCE INTERNATIONAL HOLDINGS, INC.
CY2024	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	CO
CY2024	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	84-4901299
CY2024	dei	Entity Address Address Line1 EntityAddressAddressLine1	6201 Bonhomme Road
CY2024	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 435N
CY2024	dei	Entity Address City Or Town EntityAddressCityOrTown	Houston
CY2024	dei	Entity Address State Or Province EntityAddressStateOrProvince	TX
CY2024	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	77036
CY2024	dei	City Area Code CityAreaCode	214
CY2024	dei	Local Phone Number LocalPhoneNumber	733-0868
CY2024	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2024	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2024	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2024	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2024	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2024	dei	Entity Small Business EntitySmallBusiness	true
CY2024	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2024	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
CY2024	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2024	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2024	dei	Entity Shell Company EntityShellCompany	false
CY2023Q4	dei	Entity Public Float EntityPublicFloat	3700000	usd
CY2024Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	10431749347	shares
CY2024	dei	Auditor Firm AuditorFirmId	6771
CY2024	dei	Auditor Name AuditorName	Victor Mokuolu, CPA PLLC
CY2024	dei	Auditor Location AuditorLocation	Houston, Texas
CY2024Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	755	usd
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	8913	usd
CY2024Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	20139	usd
CY2023Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	9951	usd
CY2024Q2	us-gaap	Other Assets Current OtherAssetsCurrent	598	usd
CY2023Q2	us-gaap	Other Assets Current OtherAssetsCurrent	598	usd
CY2024Q2	us-gaap	Assets Current AssetsCurrent	21492	usd
CY2023Q2	us-gaap	Assets Current AssetsCurrent	19462	usd
CY2024Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	35670	usd
CY2023Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	23920	usd
CY2024Q2	us-gaap	Assets Assets	57162	usd
CY2023Q2	us-gaap	Assets Assets	43382	usd
CY2024Q2	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	196088	usd
CY2023Q2	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	111299	usd
CY2024Q2	us-gaap	Bank Overdrafts BankOverdrafts	2408	usd
CY2023Q2	us-gaap	Bank Overdrafts BankOverdrafts	0	usd
CY2024Q2	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	0	usd
CY2023Q2	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	28641	usd
CY2024Q2	CBIH	Related Party Payables RelatedPartyPayables	503214	usd
CY2023Q2	CBIH	Related Party Payables RelatedPartyPayables	105173	usd
CY2024Q2	us-gaap	Other Short Term Borrowings OtherShortTermBorrowings	151267	usd
CY2023Q2	us-gaap	Other Short Term Borrowings OtherShortTermBorrowings	121407	usd
CY2024Q2	us-gaap	Loans Payable Current LoansPayableCurrent	7054	usd
CY2023Q2	us-gaap	Loans Payable Current LoansPayableCurrent	14592	usd
CY2024Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	21877	usd
CY2023Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	4435	usd
CY2024Q2	us-gaap	Liabilities Current LiabilitiesCurrent	881908	usd
CY2023Q2	us-gaap	Liabilities Current LiabilitiesCurrent	385547	usd
CY2024Q2	us-gaap	Long Term Loans Payable LongTermLoansPayable	249361	usd
CY2023Q2	us-gaap	Long Term Loans Payable LongTermLoansPayable	249500	usd
CY2024Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	4906	usd
CY2023Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	0	usd
CY2024Q2	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	254267	usd
CY2023Q2	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	249500	usd
CY2024Q2	us-gaap	Liabilities Liabilities	1136175	usd
CY2023Q2	us-gaap	Liabilities Liabilities	635047	usd
CY2024Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2023Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2024Q2	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2023Q2	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2024Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	20000000000	shares
CY2023Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	20000000000	shares
CY2024Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	10431749347	shares
CY2024Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	10431749347	shares
CY2023Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	10059677919	shares
CY2023Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	10059677919	shares
CY2024Q2	us-gaap	Common Stock Value CommonStockValue	0	usd
CY2023Q2	us-gaap	Common Stock Value CommonStockValue	0	usd
CY2024Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	4255068	usd
CY2023Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	4091071	usd
CY2024Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-5334081	usd
CY2023Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-4682736	usd
CY2024Q2	us-gaap	Stockholders Equity StockholdersEquity	-1079013	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	-591665	usd
CY2024Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	57162	usd
CY2023Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	43382	usd
CY2024	us-gaap	Revenues Revenues	248841	usd
CY2023	us-gaap	Revenues Revenues	316825	usd
CY2024	us-gaap	Cost Of Revenue CostOfRevenue	45599	usd
CY2023	us-gaap	Cost Of Revenue CostOfRevenue	93450	usd
CY2024	us-gaap	Gross Profit GrossProfit	203242	usd
CY2023	us-gaap	Gross Profit GrossProfit	223375	usd
CY2024	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	123759	usd
CY2023	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	177110	usd
CY2024	us-gaap	Labor And Related Expense LaborAndRelatedExpense	205984	usd
CY2023	us-gaap	Labor And Related Expense LaborAndRelatedExpense	659651	usd
CY2024	us-gaap	Professional Fees ProfessionalFees	232844	usd
CY2023	us-gaap	Professional Fees ProfessionalFees	245691	usd
CY2024	us-gaap	Officers Compensation OfficersCompensation	38000	usd
CY2023	us-gaap	Officers Compensation OfficersCompensation	45735	usd
CY2024	us-gaap	Operating Lease Expense OperatingLeaseExpense	86730	usd
CY2023	us-gaap	Operating Lease Expense OperatingLeaseExpense	71942	usd
CY2024	us-gaap	Travel And Entertainment Expense TravelAndEntertainmentExpense	2065	usd
CY2023	us-gaap	Travel And Entertainment Expense TravelAndEntertainmentExpense	6617	usd
CY2024	us-gaap	Operating Expenses OperatingExpenses	689382	usd
CY2023	us-gaap	Operating Expenses OperatingExpenses	1206746	usd
CY2024	us-gaap	Operating Income Loss OperatingIncomeLoss	-486140	usd
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-983371	usd
CY2024	CBIH	Debt Discount DebtDiscount	11000	usd
CY2023	CBIH	Debt Discount DebtDiscount	-0	usd
CY2024	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	usd
CY2023	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	41765	usd
CY2024	us-gaap	Interest Expense Nonoperating InterestExpenseNonoperating	154206	usd
CY2023	us-gaap	Interest Expense Nonoperating InterestExpenseNonoperating	90973	usd
CY2024	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-165206	usd
CY2023	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-49208	usd
CY2024	us-gaap	Net Income Loss NetIncomeLoss	-651345	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-1032579	usd
CY2024	CBIH	Payments To Sba Loan PaymentsToSbaLoan	139	usd
CY2023	CBIH	Payments To Sba Loan PaymentsToSbaLoan	-0	usd
CY2024	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	19000	usd
CY2023	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	-0	usd
CY2024	us-gaap	Proceeds From Repayments Of Related Party Debt ProceedsFromRepaymentsOfRelatedPartyDebt	398041	usd
CY2023	us-gaap	Proceeds From Repayments Of Related Party Debt ProceedsFromRepaymentsOfRelatedPartyDebt	0	usd
CY2024	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	471224	usd
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	875298	usd
CY2024	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-8158	usd
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-23069	usd
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	8913	usd
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	31982	usd
CY2024Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	755	usd
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	8913	usd
CY2024	us-gaap	Interest Paid Net InterestPaidNet	154206	usd
CY2023	us-gaap	Interest Paid Net InterestPaidNet	93472	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	-361052	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	-361052	usd
CY2023	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	801966	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-1032579	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	-591665	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	-591665	usd
CY2024	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	70000	usd
CY2024	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	75000	usd
CY2024	us-gaap	Stock Issued During Period Value Employee Benefit Plan StockIssuedDuringPeriodValueEmployeeBenefitPlan	37997	usd
CY2024	CBIH	Stcok Issued During Period Value Rescission Of Stock Sale StcokIssuedDuringPeriodValueRescissionOfStockSale	-19000	usd
CY2024	us-gaap	Net Income Loss NetIncomeLoss	-651345	usd
CY2024Q2	us-gaap	Stockholders Equity StockholdersEquity	-1079013	usd
CY2024	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	10317612225	shares
CY2024	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	10317612225	shares
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	9001539324	shares
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	9001539324	shares
CY2024	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.00006
CY2024	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.00006
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.00011
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.00011
CY2024	us-gaap	Net Income Loss NetIncomeLoss	-651345	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-1032579	usd
CY2024	CBIH	Adjustment For Issuance Of Common Stock Noncash Expense AdjustmentForIssuanceOfCommonStockNoncashExpense	112997	usd
CY2023	CBIH	Adjustment For Issuance Of Common Stock Noncash Expense AdjustmentForIssuanceOfCommonStockNoncashExpense	0	usd
CY2024	CBIH	Amortization Of Right Of Use Asset And Liability AmortizationOfRightOfUseAssetAndLiability	11750	usd
CY2023	CBIH	Amortization Of Right Of Use Asset And Liability AmortizationOfRightOfUseAssetAndLiability	-36378	usd
CY2024	us-gaap	Share Based Compensation ShareBasedCompensation	0	usd
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	12000	usd
CY2024	us-gaap	Extinguishment Of Debt Gain Loss Net Of Tax ExtinguishmentOfDebtGainLossNetOfTax	-0	usd
CY2023	us-gaap	Extinguishment Of Debt Gain Loss Net Of Tax ExtinguishmentOfDebtGainLossNetOfTax	41666	usd
CY2024	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	22348	usd
CY2023	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-43423	usd
CY2024	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	10188	usd
CY2023	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	4935	usd
CY2024	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	84789	usd
CY2023	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	43089	usd
CY2024	CBIH	Increase Decrease In Bank Overdrafts IncreaseDecreaseInBankOverdrafts	2408	usd
CY2023	CBIH	Increase Decrease In Bank Overdrafts IncreaseDecreaseInBankOverdrafts	0	usd
CY2024	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-28641	usd
CY2023	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	28641	usd
CY2024	CBIH	Increase Decrease In Accrued Interest On Sba Loan IncreaseDecreaseInAccruedInterestOnSbaLoan	0	usd
CY2023	CBIH	Increase Decrease In Accrued Interest On Sba Loan IncreaseDecreaseInAccruedInterestOnSbaLoan	21571	usd
CY2024	CBIH	Increase Decrease In Interest On Sba Loan IncreaseDecreaseInInterestOnSbaLoan	0	usd
CY2023	CBIH	Increase Decrease In Interest On Sba Loan IncreaseDecreaseInInterestOnSbaLoan	-6778	usd
CY2024	CBIH	Increase Decrease In Advances On Related Party IncreaseDecreaseInAdvancesOnRelatedParty	0	usd
CY2023	CBIH	Increase Decrease In Advances On Related Party IncreaseDecreaseInAdvancesOnRelatedParty	99015	usd
CY2024	CBIH	Increase Decrease In Repayments Of Related Party Advances IncreaseDecreaseInRepaymentsOfRelatedPartyAdvances	-0	usd
CY2023	CBIH	Increase Decrease In Repayments Of Related Party Advances IncreaseDecreaseInRepaymentsOfRelatedPartyAdvances	9680	usd
CY2024	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-479382	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-898367	usd
CY2024	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	70000	usd
CY2023	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	801966	usd
CY2024	us-gaap	Proceeds From Short Term Debt ProceedsFromShortTermDebt	29860	usd
CY2023	us-gaap	Proceeds From Short Term Debt ProceedsFromShortTermDebt	73332	usd
CY2024	CBIH	Payment Of Sba Loan Current PaymentOfSbaLoanCurrent	7538	usd
CY2023	CBIH	Payment Of Sba Loan Current PaymentOfSbaLoanCurrent	-0	usd
CY2024	CBIH	Payments To Sba Loan PaymentsToSbaLoan	139	usd
CY2024	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	19000	usd
CY2023	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	-0	usd
CY2024	us-gaap	Proceeds From Repayments Of Related Party Debt ProceedsFromRepaymentsOfRelatedPartyDebt	398041	usd
CY2023	us-gaap	Proceeds From Repayments Of Related Party Debt ProceedsFromRepaymentsOfRelatedPartyDebt	0	usd
CY2024	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	471224	usd
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	875298	usd
CY2024	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-8158	usd
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-23069	usd
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	31982	usd
CY2024Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	755	usd
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	8913	usd
CY2024	us-gaap	Interest Paid Net InterestPaidNet	154206	usd
CY2023	us-gaap	Interest Paid Net InterestPaidNet	93472	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	-361052	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	-361052	usd
CY2023	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	801966	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-1032579	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	-591665	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	-591665	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	-591665	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	-591665	usd
CY2024	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	70000	usd
CY2024	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	75000	usd
CY2024	us-gaap	Stock Issued During Period Value Employee Benefit Plan StockIssuedDuringPeriodValueEmployeeBenefitPlan	37997	usd
CY2024	CBIH	Stcok Issued During Period Value Rescission Of Stock Sale StcokIssuedDuringPeriodValueRescissionOfStockSale	-19000	usd
CY2024	us-gaap	Net Income Loss NetIncomeLoss	-651345	usd
CY2024Q2	us-gaap	Stockholders Equity StockholdersEquity	-1079013	usd
CY2024Q2	us-gaap	Stockholders Equity StockholdersEquity	-1079013	usd
CY2024	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_848_eus-gaap--UseOfEstimates_zrvYHN5hHW7a" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span id="xdx_86D_z1QNnGdNNZzh">Use of Estimates</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The preparation of financial statements in conformity with U.S. GAAP requires management to make significant estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the dates of the financial statements and the reported amounts of revenue and expenses during the reporting periods. Making estimates requires management to exercise significant judgment. Certain of these estimates could be affected by external conditions, including those unique to the Company’s businesses, and general economic conditions. These external conditions could have an effect on the Company’s estimates that could cause actual results to differ materially from its estimates. Actual results could differ from those estimates. The Company re-evaluates all of its accounting estimates at least quarterly based on these conditions and records adjustments when necessary. Significant estimates relied upon in preparing these statements include revenue recognition, accounts receivable reserves, accrued expenses, share-based compensation and the recoverability of the Company’s net deferred tax assets and any related valuation allowance.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
CY2024	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_848_eus-gaap--UseOfEstimates_zrvYHN5hHW7a" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span id="xdx_86D_z1QNnGdNNZzh">Use of Estimates</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The preparation of financial statements in conformity with U.S. GAAP requires management to make significant estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the dates of the financial statements and the reported amounts of revenue and expenses during the reporting periods. Making estimates requires management to exercise significant judgment. Certain of these estimates could be affected by external conditions, including those unique to the Company’s businesses, and general economic conditions. These external conditions could have an effect on the Company’s estimates that could cause actual results to differ materially from its estimates. Actual results could differ from those estimates. The Company re-evaluates all of its accounting estimates at least quarterly based on these conditions and records adjustments when necessary. Significant estimates relied upon in preparing these statements include revenue recognition, accounts receivable reserves, accrued expenses, share-based compensation and the recoverability of the Company’s net deferred tax assets and any related valuation allowance.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
CY2024	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<p id="xdx_845_eus-gaap--PriorPeriodReclassificationAdjustmentDescription_zVVhoQoqxjib" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="xdx_86C_zXnAFknN16af"><b>Reclassification</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Certain amounts in the prior consolidated financial statements have been reclassified to conform to the presentation of the current period financial statements. These reclassifications had no impact on the results of operations, changes in equity, or cash flows.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
CY2024Q2	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	0	usd
CY2023Q2	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	0	usd
CY2024Q2	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	0	usd
CY2023Q2	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	0	usd
CY2024	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<p id="xdx_845_eus-gaap--PriorPeriodReclassificationAdjustmentDescription_zVVhoQoqxjib" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="xdx_86C_zXnAFknN16af"><b>Reclassification</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Certain amounts in the prior consolidated financial statements have been reclassified to conform to the presentation of the current period financial statements. These reclassifications had no impact on the results of operations, changes in equity, or cash flows.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
CY2024Q2	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	0	usd
CY2023Q2	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	0	usd
CY2024Q2	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	0	usd
CY2023Q2	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	0	usd
CY2024Q2	us-gaap	Revenue Remaining Performance Obligation RevenueRemainingPerformanceObligation	0	usd
CY2023Q2	us-gaap	Revenue Remaining Performance Obligation RevenueRemainingPerformanceObligation	0	usd
CY2024Q2	us-gaap	Revenue Remaining Performance Obligation RevenueRemainingPerformanceObligation	0	usd
CY2023Q2	us-gaap	Revenue Remaining Performance Obligation RevenueRemainingPerformanceObligation	0	usd
CY2024	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	0	shares
CY2023	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	0	shares
CY2024	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	0	shares
CY2023	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	0	shares
CY2024	us-gaap	Operating Income Loss OperatingIncomeLoss	-486140	usd
CY2024	us-gaap	Net Cash Provided By Used In Continuing Operations NetCashProvidedByUsedInContinuingOperations	479382	usd
CY2024Q2	CBIH	Working Capital WorkingCapital	-860417	usd
CY2024Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-5334081	usd
CY2024	us-gaap	Operating Income Loss OperatingIncomeLoss	-486140	usd
CY2024	us-gaap	Net Cash Provided By Used In Continuing Operations NetCashProvidedByUsedInContinuingOperations	479382	usd
CY2024Q2	CBIH	Working Capital WorkingCapital	-860417	usd
CY2024Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-5334081	usd
CY2024Q2	us-gaap	Long Term Debt Current LongTermDebtCurrent	7054	usd
CY2023Q2	us-gaap	Long Term Debt Current LongTermDebtCurrent	14592	usd
CY2024Q2	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	249361	usd
CY2023Q2	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	249500	usd
CY2024Q2	us-gaap	Long Term Debt LongTermDebt	256415	usd
CY2023Q2	us-gaap	Long Term Debt LongTermDebt	264092	usd
	us-gaap	Debt Instrument Periodic Payment DebtInstrumentPeriodicPayment	6114	usd
	us-gaap	Debt Instrument Frequency Of Periodic Payment DebtInstrumentFrequencyOfPeriodicPayment	per week for 17 weeks
CY2024Q2	CBIH	Operating Lease Right Of Use Asset Before Accumulated Amortization OperatingLeaseRightOfUseAssetBeforeAccumulatedAmortization	43150	usd
CY2023Q2	CBIH	Operating Lease Right Of Use Asset Before Accumulated Amortization OperatingLeaseRightOfUseAssetBeforeAccumulatedAmortization	155387	usd
CY2024Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	35670	usd
CY2023Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	23920	usd
CY2024Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	21877	usd
CY2023Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	4435	usd
CY2024Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	4906	usd
CY2023Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	0	usd
CY2024Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	26873	usd
CY2023Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	4435	usd
CY2024	us-gaap	Operating Lease Expense OperatingLeaseExpense	86730	usd
CY2024Q2	us-gaap	Long Term Debt Current LongTermDebtCurrent	7054	usd
CY2023Q2	us-gaap	Long Term Debt Current LongTermDebtCurrent	14592	usd
CY2023Q2	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	249500	usd
CY2024Q2	us-gaap	Long Term Debt LongTermDebt	256415	usd
CY2023Q2	us-gaap	Long Term Debt LongTermDebt	264092	usd
	us-gaap	Debt Instrument Periodic Payment DebtInstrumentPeriodicPayment	6114	usd
	us-gaap	Debt Instrument Frequency Of Periodic Payment DebtInstrumentFrequencyOfPeriodicPayment	per week for 17 weeks
CY2024Q2	CBIH	Operating Lease Right Of Use Asset Before Accumulated Amortization OperatingLeaseRightOfUseAssetBeforeAccumulatedAmortization	43150	usd
CY2023Q2	CBIH	Operating Lease Right Of Use Asset Before Accumulated Amortization OperatingLeaseRightOfUseAssetBeforeAccumulatedAmortization	155387	usd
CY2024Q2	CBIH	Operating Lease Right Of Use Asset Accumulated Amortization OperatingLeaseRightOfUseAssetAccumulatedAmortization	7480	usd
CY2023Q2	CBIH	Operating Lease Right Of Use Asset Accumulated Amortization OperatingLeaseRightOfUseAssetAccumulatedAmortization	131467	usd
CY2024Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	35670	usd
CY2023Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	23920	usd
CY2024Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	21877	usd
CY2023Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	4435	usd
CY2024Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	4906	usd
CY2023Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	0	usd
CY2024Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	26873	usd
CY2023Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	4435	usd
CY2024	us-gaap	Operating Lease Expense OperatingLeaseExpense	86730	usd
CY2023	us-gaap	Operating Lease Expense OperatingLeaseExpense	71942	usd
CY2024	us-gaap	Revenues Revenues	248841	usd
CY2023	us-gaap	Revenues Revenues	316825	usd
CY2023	us-gaap	Operating Lease Expense OperatingLeaseExpense	71942	usd
CY2024	us-gaap	Revenues Revenues	248841	usd
CY2023	us-gaap	Revenues Revenues	316825	usd
CY2024	us-gaap	Cost Of Revenue CostOfRevenue	45599	usd
CY2023	us-gaap	Cost Of Revenue CostOfRevenue	93450	usd
CY2024Q2	us-gaap	Capital Units Authorized CapitalUnitsAuthorized	20010000000	shares
CY2024Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	20000000000	shares
CY2024Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	10431749347	shares
CY2024Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	10431749347	shares
CY2023Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	10059677919	shares
CY2023Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	10059677919	shares
CY2024	us-gaap	Income Tax Reconciliation Tax Settlements State And Local IncomeTaxReconciliationTaxSettlementsStateAndLocal	1120157	usd
CY2024	us-gaap	Income Tax Reconciliation Other Reconciling Items IncomeTaxReconciliationOtherReconcilingItems	-1120157	usd
CY2024	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2023	us-gaap	Income Tax Reconciliation Tax Settlements State And Local IncomeTaxReconciliationTaxSettlementsStateAndLocal	979658	usd
CY2023	us-gaap	Income Tax Reconciliation Other Reconciling Items IncomeTaxReconciliationOtherReconcilingItems	-979658	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2024Q2	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	5334081	usd
CY2023Q2	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	4682736	usd
CY2023	us-gaap	Cost Of Revenue CostOfRevenue	93450	usd
CY2024Q2	us-gaap	Capital Units Authorized CapitalUnitsAuthorized	20010000000	shares
CY2024Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	20000000000	shares
CY2024Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2024Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	10431749347	shares
CY2024Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	10431749347	shares
CY2023Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	10059677919	shares
CY2024	us-gaap	Income Tax Reconciliation Other Reconciling Items IncomeTaxReconciliationOtherReconcilingItems	-1120157	usd
CY2023	us-gaap	Income Tax Reconciliation Other Reconciling Items IncomeTaxReconciliationOtherReconcilingItems	-979658	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2024Q2	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	5334081	usd
CY2024	CBIH	Operating Leases Rent Expense Monthly Payment OperatingLeasesRentExpenseMonthlyPayment	3382	usd
CY2020Q3	CBIH	Operating Leases Rent Expense Monthly Payment OperatingLeasesRentExpenseMonthlyPayment	3529	usd
CY2021Q3	CBIH	Operating Leases Rent Expense Monthly Payment OperatingLeasesRentExpenseMonthlyPayment	3676	usd
CY2022Q3	CBIH	Operating Leases Rent Expense Monthly Payment OperatingLeasesRentExpenseMonthlyPayment	3823	usd
CY2024	us-gaap	Lessee Operating Lease Description LesseeOperatingLeaseDescription	On March 23, 2023, the Company amended the lease to extend its term to June 30, 2024, at a base rent of $4,779 per month. For information regarding the recording of the right-of-use asset and the lease liability in the balance sheets with respect to this lease, see Note 5. This lease was terminated effective May 1, 2024, and on that date, the Company leased premises of approximately 1,367 square feet located at 6201 Bonhomme Road, Suite 435N, Houston, Texas, under a lease dated April 12, 2024. This lease, which has a one-year term that commenced on May 1, 2024, provides for base rent of $1,631 per month.
CY2024	CBIH	Operating Leases Rent Expense Monthly Payment OperatingLeasesRentExpenseMonthlyPayment	3382	usd
CY2020Q3	CBIH	Operating Leases Rent Expense Monthly Payment OperatingLeasesRentExpenseMonthlyPayment	3529	usd
CY2021Q3	CBIH	Operating Leases Rent Expense Monthly Payment OperatingLeasesRentExpenseMonthlyPayment	3676	usd
CY2022Q3	CBIH	Operating Leases Rent Expense Monthly Payment OperatingLeasesRentExpenseMonthlyPayment	3823	usd
CY2024	us-gaap	Lessee Operating Lease Description LesseeOperatingLeaseDescription	On March 23, 2023, the Company amended the lease to extend its term to June 30, 2024, at a base rent of $4,779 per month. For information regarding the recording of the right-of-use asset and the lease liability in the balance sheets with respect to this lease, see Note 5. This lease was terminated effective May 1, 2024, and on that date, the Company leased premises of approximately 1,367 square feet located at 6201 Bonhomme Road, Suite 435N, Houston, Texas, under a lease dated April 12, 2024. This lease, which has a one-year term that commenced on May 1, 2024, provides for base rent of $1,631 per month.
CY2023	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	101335	usd
CY2024	CBIH	Other Liability Noncurrent Related Party1 OtherLiabilityNoncurrentRelatedParty1	503214	usd
CY2023	CBIH	Other Liability Noncurrent Related Party1 OtherLiabilityNoncurrentRelatedParty1	105173	usd
CY2023	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	101335	usd
CY2024	CBIH	Other Liability Noncurrent Related Party1 OtherLiabilityNoncurrentRelatedParty1	503214	usd
CY2023	CBIH	Other Liability Noncurrent Related Party1 OtherLiabilityNoncurrentRelatedParty1	105173	usd
CY2024	us-gaap	Revenues Revenues	248841	usd
CY2023	us-gaap	Revenues Revenues	316825	usd
CY2024Q2	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2024Q2	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2024Q2	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2024Q2	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false
CY2024	us-gaap	Revenues Revenues	248841	usd
CY2024Q2	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2024Q2	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2024Q2	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2024Q2	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false

Files In Submission

Name	View Source	Status
0001683168-24-006402-index-headers.html	Edgar Link	pending
0001683168-24-006402-index.html	Edgar Link	pending
0001683168-24-006402.txt	Edgar Link	pending
0001683168-24-006402-xbrl.zip	Edgar Link	pending
cannabisbio_ex1003.htm	Edgar Link	pending
cannabisbio_ex1013.htm	Edgar Link	pending
cannabisbio_ex1017.htm	Edgar Link	pending
cannabisbio_ex1018.htm	Edgar Link	pending
cannabisbio_ex3100.htm	Edgar Link	pending
cannabisbio_ex3200.htm	Edgar Link	pending
cannabisbio_ex9700.htm	Edgar Link	pending
cannabisbio_i10k-053124.htm	Edgar Link	pending
cbih-20240531.xsd	Edgar Link	pending
cbih-20240531_cal.xml	Edgar Link	unprocessable
cbih-20240531_def.xml	Edgar Link	unprocessable
cbih-20240531_lab.xml	Edgar Link	unprocessable
cbih-20240531_pre.xml	Edgar Link	unprocessable
cannabisbio_i10k-053124_htm.xml	Edgar Link	completed
Financial_Report.xlsx	Edgar Link	pending
image_032.jpg	Edgar Link	pending
image_033.jpg	Edgar Link	pending
image_034.jpg	Edgar Link	pending
image_035.jpg	Edgar Link	pending
image_036.jpg	Edgar Link	pending
image_037.jpg	Edgar Link	pending
image_038.jpg	Edgar Link	pending
image_039.jpg	Edgar Link	pending
image_040.jpg	Edgar Link	pending
image_042.jpg	Edgar Link	pending
image_043.jpg	Edgar Link	pending
image_044.jpg	Edgar Link	pending
image_045.jpg	Edgar Link	pending
image_046.jpg	Edgar Link	pending
image_047.jpg	Edgar Link	pending
image_048.jpg	Edgar Link	pending
image_049.jpg	Edgar Link	pending
image_050.jpg	Edgar Link	pending
image_051.jpg	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
image_053.jpg	Edgar Link	pending
image_054.jpg	Edgar Link	pending
image_055.jpg	Edgar Link	pending
image_056.jpg	Edgar Link	pending
image_057.jpg	Edgar Link	pending
image_058.jpg	Edgar Link	pending
image_059.jpg	Edgar Link	pending
image_060.jpg	Edgar Link	pending
image_061.jpg	Edgar Link	pending
image_062.jpg	Edgar Link	pending
image_063.jpg	Edgar Link	pending
image_064.jpg	Edgar Link	pending
image_065.jpg	Edgar Link	pending
image_066.jpg	Edgar Link	pending
image_067.jpg	Edgar Link	pending
image_068.jpg	Edgar Link	pending
image_069.jpg	Edgar Link	pending
image_070.jpg	Edgar Link	pending
image_071.jpg	Edgar Link	pending
image_072.jpg	Edgar Link	pending
image_073.jpg	Edgar Link	pending
image_074.jpg	Edgar Link	pending
image_075.jpg	Edgar Link	pending
image_076.jpg	Edgar Link	pending
image_077.jpg	Edgar Link	pending
image_078.jpg	Edgar Link	pending
image_079.jpg	Edgar Link	pending
image_080.jpg	Edgar Link	pending
image_081.jpg	Edgar Link	pending
image_082.jpg	Edgar Link	pending
image_083.jpg	Edgar Link	pending
image_084.jpg	Edgar Link	pending
image_085.jpg	Edgar Link	pending
image_086.jpg	Edgar Link	pending
image_087.jpg	Edgar Link	pending
image_088.jpg	Edgar Link	pending
image_089.jpg	Edgar Link	pending
image_090.jpg	Edgar Link	pending
image_091.jpg	Edgar Link	pending
image_092.jpg	Edgar Link	pending
image_093.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$CBIH
Cannabis Bioscience International Holdings, Inc. Stock $cbih

2024 Q3 Form 10-K Financial Statement

#000168316824006402 Filed on September 16, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CBIH Cannabis Bioscience International Holdings, Inc. Stock $cbih

2024 Q3 Form 10-K Financial Statement

#000168316824006402 Filed on September 16, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CBIH
Cannabis Bioscience International Holdings, Inc. Stock $cbih